Insider Trading Activity Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Director Sold 700 shares of Stock

ME Staff
-
0

Insider Trading Activity For Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Ann M Veneman , Director of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) reportedly Sold 700 shares of the company’s stock at an average price of 137.74 for a total transaction amount of $96,418.00 SEC Form

Insider Trading History For Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

  • On 10/31/2012 Patrice Coissac, SVP, sold 84,764 with an average share price of $91.16 per share and the total transaction amounting to $7,727,086.24.View SEC Filing
  • On 1/15/2013 Leonard Bell, CEO, sold 35,000 with an average share price of $98.58 per share and the total transaction amounting to $3,450,300.00.View SEC Filing
  • On 2/4/2013 Vikas Sinha, CFO, sold 3,483 with an average share price of $95.81 per share and the total transaction amounting to $333,706.23.View SEC Filing
  • On 2/4/2013 Stephen P Squinto, EVP, sold 2,572 with an average share price of $95.68 per share and the total transaction amounting to $246,088.96.View SEC Filing
  • On 2/4/2013 Leonard Bell, CEO, sold 11,880 with an average share price of $96.27 per share and the total transaction amounting to $1,143,687.60.View SEC Filing
  • On 4/10/2013 Leonard Bell, CEO, sold 26,700 with an average share price of $100.24 per share and the total transaction amounting to $2,676,408.00.View SEC Filing
  • On 5/13/2013 Leonard Bell, CEO, sold 41,220 with an average share price of $100.85 per share and the total transaction amounting to $4,157,037.00.View SEC Filing

    • Analyst Ratings For Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
    These are 5 Hold Ratings, 17 Buy Ratings, 1 Strong Buy Rating .
    The current consensus rating for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is Buy (Score: 2.83) with a consensus target price of $158.05 , a potential (14.55% upside)

    Analyst Ratings History For Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

    • On 1/7/2016 BTIG Research Downgraded rating Buy to Neutral
    • On 6/6/2016 Bank of America Corporation Reiterated Rating Buy
    • On 9/20/2016 Citigroup Inc. Boost Price Target of rating Buy with a price target of $154.00 to $155.00
    • On 10/4/2016 Brean Capital Initiated Coverage of rating Buy with a price target of $221.00
    • On 11/30/2016 FBR & Co Reiterated Rating Market Perform with a price target of $130.00
    • On 12/13/2016 Wedbush Reiterated Rating Neutral with a price target of $135.00
    • On 1/6/2017 Piper Jaffray Companies Reiterated Rating Buy with a price target of $176.00

    Recent Trading Activity for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
    Shares of Alexion Pharmaceuticals, Inc. closed the previous trading session at 137.97 up +0.18 0.13% with 1,677,581 shares trading hands.